An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine

References

• Baccarini C, Ternouth A, Wieffer H, et al. The changing epidemiology of meningococcal disease in North America 1945–2010. Hum Vacc Immunother. 2013;9(1):162–171.
   PubMed Web of Science ®Google Scholar
• Vyse A, Anonychuk A, Jäkel A, et al. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infec Ther. 2013;11(6):597–604.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Ochnio J, Ho M, et al. Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America. Emerg Infect Dis. 2004;10(10):1812–1815.
   PubMed Web of Science ®Google Scholar
• CDC – ABCs. Surveillance reports main page - active bacterial core surveillance [internet]. [updated 2016 Jun 27]. Available from: http://www.cdc.gov/abcs/reports-findings/surv-reports.html.
   Google Scholar
• Whittaker R, Dias JG, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014. Vaccine. 2017;35(16):2034–2041.
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27 Suppl 2(Suppl 2):B51–B63.
   PubMedGoogle Scholar
• Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(2 Suppl):S3–S11.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26–B36.
   PubMed Web of Science ®Google Scholar
• Borrow R, Alarcon P, Carlos J, et al. The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16(4):313–328.
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58–S67.
   PubMed Web of Science ®Google Scholar
• Hellenbrand W, Elias J, Wichmann O, et al. Epidemiology of invasive meningococcal disease in Germany, 2002–2010, and impact of vaccination with meningococcal C conjugate vaccine. J Infect. 2013;66(1):48–56.
   PubMed Web of Science ®Google Scholar
• Garrido-Estepa M, León-Gómez I, Herruzo R, et al. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification. Vaccine. 2014;32(22):2604–2609.
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Lefebvre B, et al. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J. 2011;30(7):566–569.
   PubMed Web of Science ®Google Scholar
• European Center for Disease Prevention and Control. Surveillance Report. Surveillance of invasive bacterial diseases in Europe. 2012. Available from: www.ecdc.europa.eu
   Google Scholar
• Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60(4):578–585.
   PubMed Web of Science ®Google Scholar
• Campbell H, Saliba V, Borrow R, et al. Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015. Euro Surveill. 2015;20:28.
   Google Scholar
• Abad R, López EL, Debbag R, et al. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America. Epidemiol Infect. 2014;142(12):2461–2470.
   PubMed Web of Science ®Google Scholar
• Lahra MM, Enriquez RP; National Neisseria Network. Australian meningococcal surveillance programme annual report, 2015. Commun Dis Intell Q Rep. 2016;40(4):E503–E511.
   PubMed Web of Science ®Google Scholar
• Dutch National Immunisation Programme. Meningococcal vaccine changed [internet]. [cited 2018 May 17]. Available from: https://rijksvaccinatieprogramma.nl/professionals/menacwy-vaccinatie
   Google Scholar
• Cooper B, DeTora L, Stoddard J. Menveo®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev Vaccines. 2011;10(1):21–33.
   PubMed Web of Science ®Google Scholar
• Broker M, Cooper B, Detora LM, et al. Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C, W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease. Infect Drug Resist. 2011;4:137–147.
   PubMedGoogle Scholar
• Findlow J, Bai X, Findlow H, et al. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine. 2015;33(29):3322–3330.
   PubMed Web of Science ®Google Scholar
• Kim HW, Park IH, You S, et al. Immunogenicity of menACWY-CRM in Korean military recruits: influence of tetanus-diphtheria toxoid vaccination on the vaccine response to menACWY-CRM. Yonsei Med J. 2016;57(6):1511–1516.
   PubMed Web of Science ®Google Scholar
• Ishola DA, Andrews N, Waight P, et al. Randomized trial to compare the immunogenicity and safety of a CRM or TT conjugated quadrivalent meningococcal vaccine in teenagers who received a CRM or TT conjugated serogroup C vaccine at preschool age. Pediatr Infect Dis J. 2015;34(8):865–874.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The Role of Humoral Antibodies. J Exp Med. 1969;129(6):1307–1326.
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine. 2005;23(17–18):2222–2227.
   PubMed Web of Science ®Google Scholar
• Tregnaghi M, Lopez P, Stamboulian D, et al. Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers. Int J Infect Dis. 2014;26:22–30.
   PubMed Web of Science ®Google Scholar
• Nolan TM, Nissen MD, Naz A, et al. Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age. Hum Vaccin Immunother. 2014;10(2):280–289.
   PubMed Web of Science ®Google Scholar
• Block SL, Shepard J, Garfield H, et al. Immunogenicity and safety of a 3- and 4-dose vaccination series of a meningococcal ACWY conjugate vaccine in infants: results of a phase 3b, randomized, open-label trial. Pediatr Infect Dis J. 2016;35(2):e48–e59.
   PubMed Web of Science ®Google Scholar
• Klein NP, Reisinger KS, Johnston W, et al. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J. 2012;31(1):64–71.
   PubMed Web of Science ®Google Scholar
• Klein N, Block S, Johnston W, et al. Persistence of meningococcal bactericidal antibodies and booster response at 60-months of age in children who received infant or toddler doses of MenACWY-CRM conjugate vaccine. Poster session presented at: IDWeek; 2014 Oct 8–12; Philadelphia, PA.
   Google Scholar
• Baxter R, Keshavan P, Welsch JA, et al. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants. Hum Vaccin Immunother. 2016;12(5):1300–1310.
   PubMed Web of Science ®Google Scholar
• Klein NP, Shepard J, Bedell L, et al. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine. 2012;30(26):3929–3936.
   PubMed Web of Science ®Google Scholar
• Abdelnour A, Silas PE, Lamas MR, et al. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants. Vaccine. 2014;32(8):965–972.
   PubMed Web of Science ®Google Scholar
• Block SL, Christensen S, Verma B, et al. Antibody persistence 5 years after vaccination at 2 to 10 years of age with quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination. Vaccine. 2015;33(18):2175–2182.
   PubMed Web of Science ®Google Scholar
• Gasparini R, Tregnaghi M, Keshavan P, et al. Safety and Immunogenicity of a quadrivalent meningococcal conjugate vaccine and commonly administered vaccines after coadministration. Pediatr Infect Dis J. 2016;35(1):81–93.
   PubMed Web of Science ®Google Scholar
• Blanchard-Rohner G, Snape MD, Kelly DF, et al. The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age. Vaccine. 2013;31(20):2441–2448.
   PubMed Web of Science ®Google Scholar
• Blanchard-Rohner G, Snape MD, Kelly DF, et al. Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom. Pediatr Infect Dis J. 2013;32(()7):768–776.
   PubMed Web of Science ®Google Scholar
• Huang LM, Chiu NC, Yeh SJ, et al. Immunogenicity and safety of a single dose of a CRM-conjugated meningococcal ACWY vaccine in children and adolescents aged 2–18 years in Taiwan: results of an open label study. Vaccine. 2014;32(40):5177–5184.
   PubMed Web of Science ®Google Scholar
• Ilyina N, Kharit S, Namazova-Baranova L, et al. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia. Hum Vaccin Immunother. 2014;10(8):2471–2481.
   PubMed Web of Science ®Google Scholar
• Johnston W, Essink B, Kirstein J, et al. Comparative assessment of a single dose and a 2-dose vaccination series of a quadrivalent meningococcal CRM-conjugate vaccine (MenACWY-CRM) in children 2–10 years of age. Pediatr Infect Dis J. 2016;35(1):e19–e27.
   PubMed Web of Science ®Google Scholar
• Lalwani S, Agarkhedkar S, Gogtay N, et al. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years. Int J Infect Dis. 2015;38:36–42.
   PubMed Web of Science ®Google Scholar
• MENVEO® Prescribing Information. [cited 2018 Aug 23]. Available from: https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm201349.pdf.
   Google Scholar
• Halperin SA, Gupta A, Jeanfreau R, et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age. Vaccine. 2010;28(50):7865–7872.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Menveo product information [internet]. [upated 2018 Apr 05; cited 2018 Apr 24]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001095/human_med_001323.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Lee HJ, Chung MH, Kim WJ, et al. Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults. Int J Infect Dis. 2014;28:204–210.
   PubMed Web of Science ®Google Scholar
• Baxter R, Reisinger K, Block SL, et al. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents. J Pediatr. 2014;164(6):1409–1415 e1404.
   PubMed Web of Science ®Google Scholar
• Baxter R, Reisinger K, Block SL, et al. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents. Pediatr Infect Dis J. 2014;33(11):1169–1176.
   PubMed Web of Science ®Google Scholar
• Jacobson RM, Jackson LA, Reisinger K, et al. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J. 2013;32(4):e170–e177.
   PubMed Web of Science ®Google Scholar
• Gill CJ, Baxter R, Anemona A, et al. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vaccin. 2010;6(11):881–887.
   PubMed Web of Science ®Google Scholar
• Alberer M, Burchard G, Jelinek T, et al. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults. J Travel Med. 2015;22(1):48–56.
   PubMed Web of Science ®Google Scholar
• Alberer M, Burchard G, Jelinek T, et al. Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study. Travel Med Infect Dis. 2014;12(5):485–493.
   PubMed Web of Science ®Google Scholar
• Alberer M, Burchard G, Jelinek T, et al. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults. J Travel Med. 2015;22(2):105–114.
   PubMed Web of Science ®Google Scholar
• Kimura A, Toneatto D, Kleinschmidt A, et al. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18(3):483–486.
   PubMed Web of Science ®Google Scholar
• Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384(9960):2123–2131.
   PubMed Web of Science ®Google Scholar
• Read RC, Dull P, Bai X, et al. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Vaccine. 2017;35(3):427–434.
   PubMed Web of Science ®Google Scholar
• Mayet A, Duron S, Meynard JB, et al. Surveillance of adverse events following vaccination in the French armed forces, 2011–2012. Public Health. 2015;129(6):763–768.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Sy LS, Ackerson BK, et al. Safety of quadrivalent meningococcal conjugate vaccine in children 2–10 years. Pediatr Infect Dis J. 2017;36(11):1087–1092.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Sy LS, Ackerson BK, et al. Safety of quadrivalent meningococcal conjugate vaccine in 11- to 21-year-olds. Pediatrics. 2017;139:1.
   Web of Science ®Google Scholar
• Myers TR, McNeil MM, Ng CS, et al. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010–2015. Vaccine. 2017;35(14):1758–1763.
   PubMed Web of Science ®Google Scholar
• Muse D, Christensen S, Bhuyan P, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35(6):673–682.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009;28(2):86–91.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Bianco V, et al. Immunogenicity, safety and antibody persistence of a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine compared with monovalent meningococcal serogroup C vaccine administered four years after primary vaccination using the same vaccines. Pediatr Infect Dis J. 2015;34(12):e298–e307.
   PubMed Web of Science ®Google Scholar
• Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet. 2014;383(9911):40–47.
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Ba AK, Ouedraogo AS, et al. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac. BMC Infect Dis. 2014;14:663.
   PubMed Web of Science ®Google Scholar
• Price G, Plikaytis B, Hollander A, et al. Comparison of different serogroup A immunoassays following a single dose of either MenAfriVac or quadrivalent polysaccharide vaccine in healthy Africans 2- to 29- years of age. Presented at International Pathogenic Neisseria Conferences, 2014 Asheville NC, USA. [cited 2016 Feb 9]. Available from: http://neisseria.org/ipnc/2014/IPNC_2014_abstracts.pdf.
   Google Scholar
• Borrow R, Abad R, Trotter C, et al. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine. 2013;31(41):4477–4486.
   PubMed Web of Science ®Google Scholar
• Macneil JR, Cohn AC, Zell ER, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30(6):451–455.
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunisation. Minute of the meeting on 01 February 2017 [internet]. [cited 2017 Aug 07]. Available from: http://www.nitag-resource.org/uploads/media/default/0001/04/3d9769b85796db91fb8ec14df1c0f790ca08fc76.pdf
   Google Scholar
• Weidlich L, Baethgen LF, Mayer LW, et al. High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W135: P1.5,2:ST-11clone in Southern Brazil. J Infect. 2008;57(4):324–331.
   PubMed Web of Science ®Google Scholar
• Ministerio de Salud (MinSalud). Fundamentos de la introducción de la vacuna tetravelente (ACYW) conjugada contra meningococo al Calendario Nacional de Inmunizaciones. Argentina; 2016. Available from: http://www.msal.gob.ar/images/stories/bes/graficos/0000000927cnt-2016-12_lineamientos-meningo.pdf
   Google Scholar
• Khatami A, Snape MD, Davis E, et al. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine. 2012;30(18):2831–2838.
   PubMed Web of Science ®Google Scholar
• Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12–59 Months [internet]. [updated 2015 Nov 6; cited 2017 Nov 26]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00310817.
   Google Scholar
• Ramasamy MN, Clutterbuck EA, Haworth K, et al. Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom. Clin Vaccine Immunol. 2014;21(8):1164–1168.
   PubMed Web of Science ®Google Scholar
• Gasparini R, Conversano M, Bona G, et al. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol. 2010;17(4):537–544.
   PubMed Web of Science ®Google Scholar